Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Wiendl, H.
Butzkueven, H.
Trojano, M.
Goodin, D.
Kappos, L.
Desgrandchamps, D.
机构：
[1] Univ Wurzburg, Wurzburg, Germany
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Univ Bari, Bari, Italy
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
[6] Biogen Idec Int GmbH, Zug, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [41] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
    Huntemann, Niklas
    Mueller, Marc
    Masanneck, Lars
    Baumgart, Romy
    Axhausen, Franziska
    Wolff, Stephanie
    Kutsojannis, Bela
    Koelsche, Tristan
    Korsen, Melanie
    Pfeuffer, Steffen
    Meuth, Sven
    Pawlitzki, Marc
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
  • [42] Safety and Impact on Disease Outcomes of Natalizumab in Patients with Relapsing-Remitting MS in Clinical Practice
    Butzkueven, Helmut
    Kappos, Ludwig
    Trojano, Maria
    Wiendl, Heinz
    Pellegrini, Fabio
    Belachew, Shibeshih
    Pace, Amy
    Desgrandchamps, Daniel
    NEUROLOGY, 2010, 74 (09) : A66 - A66
  • [43] Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis
    Perumal, Jai
    Balabanov, Roumen
    Balcer, Laura
    Galetta, Steven
    Sun, Zhaonan
    Li, Hanyue
    Rutledge, Danette
    Avila, Robin L.
    Fox, Robert J.
    NEUROLOGY AND THERAPY, 2023, 12 (03) : 833 - 848
  • [44] Case History Long-Term Treatment of relapsing-remitting MS with Natalizumab
    Sievers, Carsten
    NERVENHEILKUNDE, 2013, 32 (10) : 786 - 786
  • [45] Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
    Meuth, Sven G.
    Bittner, Stefan
    Seiler, Carola
    Goebel, Kerstin
    Wiendl, Heinz
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 198 - 203
  • [46] Real-world data from over 10 years in the TYSABRI® Observational Program: long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients
    Kappos, L.
    Butzkueven, H.
    Spelman, T.
    Trojano, M.
    Wiendl, H.
    Jiang, X.
    Kasliwal, R.
    Campbell, N.
    Ho, P. -R.
    Licata, S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 489 - 489
  • [47] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
    Matveev, N., V
    Sabanov, A., V
    Luneva, A., V
    VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
  • [48] Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing-Remitting Multiple Sclerosis
    Escribano, Begona M.
    Aguilar-Luque, Macarena
    Bahamonde, Carmen
    Conde, Cristina
    Lillo, Rafael
    Sanchez-Lopez, Fernando
    Giraldo, Ana I.
    Cruz, Antonio H.
    Luque, Evelio
    Gascon, Felix
    Aguera, Eduardo
    Tunez, Isaac
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (31) : 4876 - 4880
  • [49] Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
    Bittner, S.
    Meuth, S.
    Seiler, C.
    Reiners, K.
    Wiendl, H.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
  • [50] The impact of long-term treatment with disease modifying therapy on disability progression in relapsing-remitting multiple sclerosis patients
    Carra, Adriana J.
    Onaha, Patricia S.
    Sinay, Vladimiro
    Halfon, Mario J.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S36 - S36
12345